STOCK TITAN

Codiak Biosciences (CDAK) Stock News, Oct-Nov 2020

CDAK NASDAQ
Rhea-AI Summary

Codiak BioSciences (NASDAQ: CDAK) announced significant operational progress in its Q3 2020 financial results, with total revenues reaching $1.0 million, up from $0.2 million in Q3 2019. The company initiated clinical trials for exoIL-12 and exoSTING, with key safety and efficacy data expected by mid-2021. Despite a net loss of $35.3 million, increased R&D expenses of $30.7 million were attributed to clinical trial activities. The recent IPO generated $74.4 million in net proceeds, supporting ongoing development and operational momentum.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
-
Rhea-AI Summary

Codiak BioSciences (NASDAQ: CDAK) presents preclinical data at the SITC 2020, showcasing its engEx™ Platform's capabilities for engineered exosome therapeutics. Key findings highlight that the exoIL-12 candidate exhibits 15-fold improved retention at injection sites and 100-fold enhanced tumor growth inhibition compared to recombinant IL-12. The candidate's administration resulted in significant infiltration of cytotoxic T-cells and M1 macrophages, indicating enhanced immune activity. Clinical trials for exoIL-12 and exoSTING™ began in September 2020, with preliminary results expected by the end of the year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.20%
Tags
-
Rhea-AI Summary

Codiak BioSciences has announced its initial public offering (IPO) of 5,500,000 shares at $15.00 per share, aiming for gross proceeds of approximately $82.5 million. The offering will begin trading on the Nasdaq under the symbol CDAK on October 14, 2020, with expected closing on October 16, 2020. Codiak has also granted underwriters a 30-day option for up to 825,000 additional shares. The company is focused on developing exosome-based therapeutics through its proprietary engEx Platform, targeting various diseases including oncology and neurology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags